One skirt size increase every 10 years elevates breast cancer risk
the ONA take:
According to a new study published in the journal BMJ Open, women whose skirt size increases one size every 10 years between their mid-20s and mid-60s have a 33% increased risk for developing breast cancer after menopause.
Researchers at University College London in London, United Kingdom, surveyed 92,834 women aged 50-69 years who were involved with the UK Collaborative Trial of Ovarian Cancer Screening about their present and previous skirt sizes. No participants had been diagnosed with breast cancer. On average, women had a skirt size of 8 at age 25 and a skirt size of 10 at age 64.
The researchers followed up with the women for 3 years and during that period, 1,090 women were diagnosed with breast cancer. The researchers estimated that the 5-year absolute risk of breast cancer in postmenopausal women increases with every one skirt size increase every 10 years.
In addition to the 33% increased risk for postmenopausal women whose skirt size increases one unit every decade, women whose skirt size increases two units every 10 years had a 77% increased risk for developing breast cancer post-menopause. They also found that body mass index did not help improve the prediction risk.
Women whose skirt size increases one size have increased risk for developing breast cancer.
Women who go up one skirt size every 10 years between their mid-20s and mid-60s are at a 33% greater risk of developing breast cancer after the menopause, new research has found.
Weight gain measured through an increase in body mass index (BMI) was known to be a risk factor, particularly around the midriff, but a study of 90,000 women is the first to make a connection between breast cancer and skirt size.
The results show that an expanding waistline could be more harmful. Those who went up by two sizes every decade in the same period saw an increased risk of 77%, according to the University College London study.The research could provide a valuable insight into breast cancer prevention.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|